Printer Friendly

Amersham Biosciences Introduces New CodeLink Human P450 SNP Bioarray for Broad-based Toxicogenomic Screening.

Business Editors/Health/Medical Writers



Most Comprehensive Coverage of the P450 Drug Metabolizing Genes

Offered to Date

Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), today announced the addition of the new CodeLink(TM) Human P450 SNP Bioarray to its existing CodeLink expression and SNP bioarray range. The CodeLink Human P450 SNP Bioarray genotypes 110 single nucleotide polymorphisms (SNPs) within nine P450 genes (CYP1A1, 1A2, 1B1, 2C9, 2C19, 2D6, 2E, 3A4, and 3A5) offering comprehensive coverage of the P450 drug metabolism genes for research applications in genotyping and pharmacogenomic profiling.

The CodeLink Human P450 SNP Bioarray is designed for screening clinical trial populations to determine their toxicogenetic profiles and for the discovery of novel associations between P450 genotypes and phenotypes. To maximize throughput, the bioarray contains a set of four identical arrays of 110 SNPs to enable the testing of four individual samples simultaneously. Customers benefit from the speed and flexibility of the system and the ability to individually score each sample with high accuracy.

"The new CodeLink Human P450 SNP Bioarray will aid the discovery of clinically significant genetic markers in populations studies for researchers involved in high throughput toxicogenomic screening ,'" said Sam Raha, Vice President CodeLink at Amersham Biosciences. "An extension to our existing CodeLink line, the design of this new bioarray maximizes throughput and minimizes labor and cost with the ability to process four different samples on each bioarray simultaneously."

Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at

Amersham Biosciences--enabling molecular medicine
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 10, 2003
Previous Article:S&P Global Credit Markets Digest -- European Update.
Next Article:Bitstream Licenses Font Fusion to PubliTronic; Worldwide Provider of Multimedia Broadcasting Solutions Licenses Bitstream's Premier Font Rendering...

Related Articles
Amersham plc Purchases Motorola Life Science's CodeLink Pre-arrayed Slides Business.
Amersham Biosciences Is Exclusive Provider of SurModics Slides; 3-Dimensional Surface Enhances Hybridization in Microarray Studies.
Toxicogenomics: an emerging discipline. (Focus).
Application of toxicogenomic analysis to risk assessment of delayed long-term effects of multiple chemicals, including endocrine disruptors in human...
GenUs BioSystems to Provide Outsourced Gene Expression Profiling.
New High Density CodeLink Uniset Mouse Bioarray from Amersham Biosciences.
Amersham Expands Scope of Its Licence to DNA Microarray Patents from Oxford Gene Technology.
EMBL Selects CodeLink for Its Study of Molecular Mechanisms in Tumor Growth.
Amersham Biosciences Advances Analysis of Gene Expression with New CodeLink Human Whole Genome Bioarray.
Ambion and GE Healthcare Announce Licensing and Supply Agreement to Advance microRNA Microarray Research.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters